Breanna Noffsinger1, Alexandra Witter1, Natasha Sheybani2, Aizhen Xiao3, Laryssa Manigat1, Qing Zhong3, Suchet Taori4, Tajie Harris4, Tim Bullock1, Richard Price2, Benjamin Purow5. 1. Department of Pathology, University of Virginia, Charlottesville, VA, USA. 2. Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA. 3. Department of Neurology, University of Virginia, Charlottesville, VA, USA. 4. Department of Neuroscience, University of Virginia, Charlottesville, VA, USA. 5. Department of Neurology, University of Virginia, Charlottesville, VA, USA. bwp5g@virginia.edu.
Abstract
PURPOSE: Due to the recent rise in immunotherapy research to treat glioblastoma (GBM), immunocompetent mouse models have become increasingly crucial. However, the character and kinetics of the immune response against the most prevalent immunocompetent GBM models, GL261 and CT2A, have not been well studied, nor has the impact of commonly-used marker proteins and foreign antigens. METHODS: In this study, we compared the immune response in these models using flow cytometry and immunohistochemistry as well as investigated several factors that influence the immune response, including kinetics, tumor size, and expression of commonly-used marker proteins and foreign antigens. We hypothesize that these factors influence the immune response enough to warrant consideration when studying new immunotherapeutic approaches for GBM. RESULTS: CT2A-Luc, but not GL261-Luc2, drastically increased the number of T cells in the brain compared with wild-type controls, and significantly altered CT2A's responsiveness to anti-PD-1 antibody therapy. Additionally, a larger cell inoculum size in the GL261 model increased the T cell response's magnitude at day 28 post-injection. CT2A and GL261 models both stimulate a peak T cell immune response at day 21 post-injection. CONCLUSIONS: Our results suggest that the impact of foreign proteins like luciferase on the intracranial immune response is dependent upon the model, with CT2A being more sensitive to added markers. In particular, luciferase expression in CT2A could lead to meaningful misinterpretations of results from immune checkpoint inhibitor (ICI) studies.
PURPOSE: Due to the recent rise in immunotherapy research to treat glioblastoma (GBM), immunocompetent mouse models have become increasingly crucial. However, the character and kinetics of the immune response against the most prevalent immunocompetent GBM models, GL261 and CT2A, have not been well studied, nor has the impact of commonly-used marker proteins and foreign antigens. METHODS: In this study, we compared the immune response in these models using flow cytometry and immunohistochemistry as well as investigated several factors that influence the immune response, including kinetics, tumor size, and expression of commonly-used marker proteins and foreign antigens. We hypothesize that these factors influence the immune response enough to warrant consideration when studying new immunotherapeutic approaches for GBM. RESULTS: CT2A-Luc, but not GL261-Luc2, drastically increased the number of T cells in the brain compared with wild-type controls, and significantly altered CT2A's responsiveness to anti-PD-1 antibody therapy. Additionally, a larger cell inoculum size in the GL261 model increased the T cell response's magnitude at day 28 post-injection. CT2A and GL261 models both stimulate a peak T cell immune response at day 21 post-injection. CONCLUSIONS: Our results suggest that the impact of foreign proteins like luciferase on the intracranial immune response is dependent upon the model, with CT2A being more sensitive to added markers. In particular, luciferase expression in CT2A could lead to meaningful misinterpretations of results from immune checkpoint inhibitor (ICI) studies.
Authors: M Bellone; D Cantarella; P Castiglioni; M C Crosti; A Ronchetti; M Moro; M P Garancini; G Casorati; P Dellabona Journal: J Immunol Date: 2000-09-01 Impact factor: 5.422
Authors: Peter Bankhead; Maurice B Loughrey; José A Fernández; Yvonne Dombrowski; Darragh G McArt; Philip D Dunne; Stephen McQuaid; Ronan T Gray; Liam J Murray; Helen G Coleman; Jacqueline A James; Manuel Salto-Tellez; Peter W Hamilton Journal: Sci Rep Date: 2017-12-04 Impact factor: 4.379
Authors: V P Baklaushev; A Kilpeläinen; S Petkov; M A Abakumov; N F Grinenko; G M Yusubalieva; A A Latanova; I L Gubskiy; F G Zabozlaev; E S Starodubova; T O Abakumova; M G Isaguliants; V P Chekhonin Journal: Sci Rep Date: 2017-08-10 Impact factor: 4.379
Authors: Zineb Belcaid; Cor Berrevoets; John Choi; Edward van Beelen; Eftychia Stavrakaki; Tessa Pierson; Jenneke Kloezeman; Denis Routkevitch; Mariëlle van der Kaaij; Alicia van der Ploeg; Dimitrios Mathios; Stefan Sleijfer; Clemens Dirven; Michael Lim; Reno Debets; Martine L M Lamfers Journal: Neurooncol Adv Date: 2020-02-03
Authors: Shawn T Beug; Caroline E Beauregard; Cristin Healy; Tarun Sanda; Martine St-Jean; Janelle Chabot; Danielle E Walker; Aditya Mohan; Nathalie Earl; Xueqing Lun; Donna L Senger; Stephen M Robbins; Peter Staeheli; Peter A Forsyth; Tommy Alain; Eric C LaCasse; Robert G Korneluk Journal: Nat Commun Date: 2017-02-15 Impact factor: 17.694